May 21, 2024

Intravenous Immunoglobulin Market Size Analysis 2023 To 2032

The global intravenous immunoglobulin market size accounted for US$ 13.69 Bn in 2022 and is projected to reach around USD 29.53 Bn by 2032, growing at a CAGR of 7.99% from 2023 to 2032.

Intravenous Immunoglobulin Market Size 2023 To 2032

Report Summary

The global intravenous immunoglobulin market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.

The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the intravenous immunoglobulin market across the globe.

A comprehensive estimate on the intravenous immunoglobulin market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of intravenous immunoglobulin during the forecast period. Price point comparison by region with global average price is also considered in the study.

Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2996

Intravenous Immunoglobulin Market Report Scope 

Report CoverageDetails
Market Size in 2023USD 14.78 Billion
Market Size by 2032USD 29.53 Billion
Growth Rate from 2023 to 2032CAGR of 7.99%
Largest MarketNorth America
Base Year2022
Forecast Period2023 to 2032
Segments CoveredBy Product, By Route of Administration, By Application, By End-Users, and By Distribution Channel
Regions CoveredNorth America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

Key Highlights:

Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized intravenous immunoglobulin market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.

Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.

Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.

Also Read: High Barrier Packaging Films Market Size Analysis 2023 To 2032

Intravenous Immunoglobulin Market Players

The report includes the profiles of key intravenous immunoglobulin market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.

Major companies operating in this area

  • Biotest AG
  • Octapharma AG
  • LFB Biotechnologies
  • Grifols SA
  • CSL Behring
  • China Biologics Products Inc.
  • Kedrion Biopharma
  • BDI Pharma Inc.

Market Segmentation

By Product

  • IGG
  • IGA
  • IGM
  • IGE
  • IGD

By Route of Administration

  • Intravenous
  • Subcutaneous

By Application

  • Hypogammaglobulinemia
  • Chronic Inflammatory demyelinating polyneuropathy (CIDP)
  • Immunodeficiency diseases
  • Myasthenia Gravis
  • Multifocal motor neuropathy
  • Idiopathic thrombocytopenic purpura (ITP)
  • Inflammatory myopathies
  • Specific antibody deficiency
  • Guillain-Barre syndrome

By End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacies

Regional Segmentation

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
  • Latin America (Brazil and Rest of Latin America)
  • Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)

Research Methodology

Secondary Research

It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.

The secondary research sources referred in the process are as follows:

  • Governmental bodies, and organizations creating economic policies
  • National and international social welfare institutions
  • Company websites, financial reports and SEC filings, broker and investor reports
  • Related patent and regulatory databases
  • Statistical databases and market reports
  • Corporate Presentations, news, press release, and specification sheet of Manufacturers

Primary Research

Primary research includes face-to-face interviews, online surveys, and telephonic interviews.

  • Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
  • In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Intravenous Immunoglobulin Market 

5.1. COVID-19 Landscape: Intravenous Immunoglobulin Industry Impact

5.2. COVID 19 – Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Intravenous Immunoglobulin Market, By Product

8.1. Intravenous Immunoglobulin Market Revenue and Volume, by Product, 2023-2032

8.1.1. IGG

8.1.1.1. Market Revenue and Volume Forecast (2020-2032)

8.1.2. IGA

8.1.2.1. Market Revenue and Volume Forecast (2020-2032)

8.1.3. IGM

8.1.3.1. Market Revenue and Volume Forecast (2020-2032)

8.1.4. IGE

8.1.4.1. Market Revenue and Volume Forecast (2020-2032)

8.1.5. IGD

8.1.5.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 9. Global Intravenous Immunoglobulin Market, By Route of Administration

9.1. Intravenous Immunoglobulin Market Revenue and Volume, by Route of Administration, 2023-2032

9.1.1. Intravenous

9.1.1.1. Market Revenue and Volume Forecast (2020-2032)

9.1.2. Subcutaneous

9.1.2.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 10. Global Intravenous Immunoglobulin Market, By Application 

10.1. Intravenous Immunoglobulin Market Revenue and Volume, by Application, 2023-2032

10.1.1. Hypogammaglobulinemia

10.1.1.1. Market Revenue and Volume Forecast (2020-2032)

10.1.2. Chronic Inflammatory demyelinating polyneuropathy (CIDP)

10.1.2.1. Market Revenue and Volume Forecast (2020-2032)

10.1.3. Immunodeficiency diseases

10.1.3.1. Market Revenue and Volume Forecast (2020-2032)

10.1.4. Myasthenia Gravis

10.1.4.1. Market Revenue and Volume Forecast (2020-2032)

10.1.5. Multifocal motor neuropathy

10.1.5.1. Market Revenue and Volume Forecast (2020-2032)

10.1.6. Idiopathic thrombocytopenic purpura (ITP)

10.1.6.1. Market Revenue and Volume Forecast (2020-2032)

10.1.7. Inflammatory myopathies

10.1.7.1. Market Revenue and Volume Forecast (2020-2032)

10.1.8. Specific antibody deficiency

10.1.8.1. Market Revenue and Volume Forecast (2020-2032)

10.1.9. Guillain-Barre syndrome

10.1.9.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 11. Global Intravenous Immunoglobulin Market, By End-Users

11.1. Intravenous Immunoglobulin Market Revenue and Volume, by End-Users, 2023-2032

11.1.1. Hospitals

11.1.1.1. Market Revenue and Volume Forecast (2020-2032)

11.1.2. Homecare

11.1.2.1. Market Revenue and Volume Forecast (2020-2032)

11.1.3. Specialty Clinics

11.1.3.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 12. Global Intravenous Immunoglobulin Market, By Distribution Channel

12.1. Intravenous Immunoglobulin Market Revenue and Volume, by Distribution Channel, 2023-2032

12.1.1. Hospital Pharmacy

12.1.1.1. Market Revenue and Volume Forecast (2020-2032)

12.1.2. Retail Pharmacy

12.1.2.1. Market Revenue and Volume Forecast (2020-2032)

12.1.3. Online Pharmacies

12.1.3.1. Market Revenue and Volume Forecast (2020-2032)

Chapter 13. Global Intravenous Immunoglobulin Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.1.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.1.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.1.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.1.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.1.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.1.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.1.6.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.1.7.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.1.7.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.1.7.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.2.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.2.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.2.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.2.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.2.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.2.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.2.7. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.2.8. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.2.9.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.2.9.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.2.10. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.2.11. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.2.12.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.2.12.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.2.12.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.2.13. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.2.14.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.2.14.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.2.14.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.2.15. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.3.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.3.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.3.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.3.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.3.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.3.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.3.6.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.3.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.3.8.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.3.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.3.8.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.3.9. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.3.10.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.3.10.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.3.10.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.3.11.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.3.11.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.3.11.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.4.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.4.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.4.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.4.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.4.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.4.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.4.6.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.4.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.4.8.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.4.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.4.8.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.4.9. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.4.10.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.4.10.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.4.10.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.4.11.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.4.11.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.4.11.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.5.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.5.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.5.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.5.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.5.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.5.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.5.6.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.5.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Product (2020-2032)

13.5.8.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)

13.5.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)

13.5.8.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)

13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)

Chapter 14. Company Profiles

14.1. Biotest AG

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Octapharma AG

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. LFB Biotechnologies

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Grifols SA

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. CSL Behring

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. China Biologics Products Inc.

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Kedrion Biopharma

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. BDI Pharma Inc.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Emailsales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com